Imatinib Accord

Imatinib, the active ingredient in Imatinib Accord, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients and is administered under medical supervision.

GNH USA supplies Imatinib Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from consistent product availability and regulatory compliance across markets.

Imatinib acts on BCR‑ABL and related kinases, providing targeted therapy for specific hematologic and solid tumours.

- Chronic myeloid leukemia (CML): achieves hematologic and cytogenetic remission, improving survival. - Gastrointestinal stromal tumor (GIST): inhibits tumor proliferation and extends progression‑free survival.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Edema - Fatigue

Serious or Rare Side Effects: - Hepatotoxicity (elevated liver enzymes) - Severe neutropenia or thrombocytopenia - Cardiac failure or left ventricular dysfunction

When prescribing Imatinib, clinicians should observe several safety measures.

- Monitor blood counts: perform regular CBC to detect neutropenia or anemia. - Assess liver function: check ALT/AST periodically for hepatotoxicity. - Evaluate cardiac status: baseline and periodic echocardiograms for heart‑failure risk. - Use caution in renal impairment: adjust dose if severe renal dysfunction is present. - Avoid in patients with known hypersensitivity to imatinib or its excipients. - Store at room temperature: keep in original packaging, protect from moisture and light.

Imatinib interacts with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase imatinib plasma levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce efficacy. - Antacids containing aluminum or magnesium: may decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Digoxin: possible increased serum concentration, monitor levels. - Oral contraceptives: reduced effectiveness, consider alternative contraception. - Proton pump inhibitors: may modestly affect imatinib exposure, observe clinical response.